LUNG
Pulmonx Hits Growth Milestone: 6% Revenue Increase in Q3 2026
Pulmonx, a leading innovator in lung cancer treatment, has achieved a significant milestone in its third quarter of 2026. The company has reported a 6% increase in total worldwide revenue to $22.8 million, marking its return to revenue growth. According to Glenn French, President and Chief Executive Officer of